Mounjaro Cost in Washington 2026: Prices, Insurance, and Savings Options

Retail Cash Price at Washington Pharmacies

The manufacturer list price set by Eli Lilly for Mounjaro is $1,023 per month, and Washington retail pharmacies charge this amount uniformly across all dose strengths (2.5 mg through 15 mg) [1]. This price applies whether you fill at a chain pharmacy in Seattle, a Costco in Spokane, or an independent pharmacy in Tacoma. The single-dose pen format means there is no per-unit price variation between lower and higher doses.

This pricing structure differs from older injectables like insulin, where vial sizes create price tiers. Eli Lilly packages each weekly dose identically regardless of milligram strength. A patient starting at 2.5 mg pays the same $1,023 as someone on the maximum 15 mg maintenance dose. Four pens come in each monthly carton, corresponding to four weekly injections [1].

Without any form of coverage or discount, an annual Mounjaro regimen costs $12,276. That figure puts tirzepatide among the most expensive GLP-1 receptor agonist therapies at list price, though Novo Nordisk's semaglutide products (Ozempic, Wegovy) fall in a comparable range [2].

Insurance Coverage in Washington State

Most major commercial insurers in Washington cover Mounjaro for type 2 diabetes with an A1c-based prior authorization requirement. Plans from Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, Molina Healthcare, and Coordinated Care typically require documentation of A1c at or above 7.0% and failure of at least one first-line agent (usually metformin) before approving tirzepatide [3].

Coverage for weight management alone remains inconsistent across Washington commercial plans. Some self-funded employer plans have added obesity as a covered indication since Zepbound (the obesity-labeled tirzepatide product) received FDA approval in November 2023 [4]. Patients seeking coverage for weight loss should verify whether their specific plan lists obesity pharmacotherapy as a covered benefit. The Washington State Office of the Insurance Commissioner does not mandate obesity drug coverage for fully insured plans.

Step therapy requirements vary. Some Washington insurers require 90 days on a GLP-1 monotherapy (semaglutide or liraglutide) before authorizing dual GIP/GLP-1 therapy with tirzepatide. Others allow direct initiation. Your prescriber's office can submit a benefits investigation through Eli Lilly's support hub to determine exact step therapy requirements for your specific plan.

Washington Medicaid (Apple Health) Coverage

Washington Medicaid, administered through Apple Health managed care organizations, covers Mounjaro with prior authorization for type 2 diabetes [5]. The Washington Health Care Authority Pharmacy and Therapeutics Committee added tirzepatide to the preferred drug list following review of the SURPASS trial program data.

Prior authorization criteria for Apple Health require: a confirmed diagnosis of type 2 diabetes mellitus, documented inadequate glycemic control (A1c above target despite metformin therapy or documented metformin intolerance), and prescribing by or in consultation with an endocrinologist or primary care provider managing diabetes. The PA is valid for 12 months and requires renewal with updated A1c documentation [5].

Off-label use for weight management alone is not covered under Washington Medicaid. Patients with both type 2 diabetes and obesity can access Mounjaro through the diabetes indication without needing a separate obesity diagnosis on the claim.

The Eli Lilly Savings Card Program

Eli Lilly's Mounjaro Savings Card reduces out-of-pocket cost to $25 per monthly fill for commercially insured patients whose plans cover the medication [6]. The card cannot be combined with government insurance (Medicare, Medicaid, Tricare, or VA benefits). Eligibility requires active commercial insurance with Mounjaro on formulary.

How activation works: patients register at the Lilly savings card portal, receive a BIN/PCN/Group number, and present this at the pharmacy alongside their insurance card. The savings card functions as secondary coverage, paying the difference between the insurance copay and $25. Maximum annual benefit is $150 per fill for up to 24 fills (covering a full year of monthly prescriptions if the copay exceeds $25).

For uninsured patients, Eli Lilly previously offered a separate cash-pay savings program at $550 per month, but availability of this program fluctuates. As of early 2026, the primary savings vehicle remains the insurance-paired card. Washington residents should check the Lilly website or call 1-800-LillyRx for current uninsured pricing offers.

Compounded Tirzepatide in Washington

Compounded tirzepatide is legal in Washington through licensed 503A compounding pharmacies [7]. These pharmacies operate under individual patient prescriptions from licensed prescribers and are regulated by the Washington State Department of Health Pharmacy Quality Assurance Commission.

Pricing for compounded tirzepatide in Washington averages $249 per month, though individual pharmacies set their own rates. Some telehealth-affiliated compounding pharmacies charge between $199 and $399 per month depending on dose, subscription model, and whether clinical consultations are bundled.

The FDA's position on compounded tirzepatide shifted in late 2024 when tirzepatide was removed from the drug shortage list [8]. Following removal, the FDA issued guidance indicating that 503A pharmacies may continue compounding tirzepatide only under traditional compounding authority (patient-specific prescriptions based on individual medical need), not under shortage-based bulk compounding permissions. Washington state law permits 503A compounding consistent with federal regulations, so patient-specific compounded tirzepatide remains available through Washington-licensed pharmacies operating within these parameters.

Patients considering compounded tirzepatide should verify that their pharmacy holds an active Washington state compounding license, uses USP 797-compliant sterile compounding facilities, and sources tirzepatide active pharmaceutical ingredient from FDA-registered suppliers. Dr. Robert Califf, former FDA Commissioner, stated in 2024 that "patients deserve assurance that compounded products meet the same quality standards expected of approved drugs" [8].

Telehealth Access for Washington Residents

Washington state permits telehealth prescribing of Mounjaro and compounded tirzepatide without requiring an in-person visit [9]. The Washington Telehealth Collaborative and state prescribing laws allow synchronous video or audio-only consultations for initiating and managing GLP-1 receptor agonist therapy.

Multiple telehealth platforms serve Washington patients for tirzepatide prescriptions. These range from Eli Lilly's own LillyDirect platform (which ships brand-name Mounjaro or Zepbound directly) to independent telehealth companies that prescribe compounded tirzepatide through partner 503A pharmacies. Pricing for telehealth consultations varies from $0 (included in medication subscription) to $149 for initial evaluation.

Washington's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, meaning a telehealth consultation to initiate Mounjaro should be covered at the same tier as an office visit under most commercial plans [9].

Cost Comparison: Brand vs. Compounded vs. Savings Card

The effective monthly cost of tirzepatide in Washington depends entirely on your coverage situation. A patient with commercial insurance and the Lilly savings card pays $25. That same patient without the savings card might pay $150 to $300 in copay depending on formulary tier (typically specialty tier 4 or 5). An uninsured patient at retail pays $1,023. A patient using compounded tirzepatide pays approximately $249.

These price differences matter clinically because tirzepatide therapy is long-term. In SURPASS-2 (N=1,879), patients on tirzepatide 15 mg achieved a mean A1c reduction of 2.58% at 40 weeks compared to 1.86% with semaglutide 1 mg [10]. Weight loss averaged 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide [10]. These outcomes require sustained therapy. Discontinuation leads to weight regain of approximately two-thirds of lost weight within one year, per data from SURMOUNT-4 [11].

For a Washington patient weighing treatment options financially, the calculus looks like this: if your insurance covers Mounjaro and you qualify for the savings card, brand-name product at $25 per month is the clear choice. If uninsured or facing high copays without savings card eligibility, compounded tirzepatide at $249 offers the same molecule at roughly 75% savings versus list price.

How to Lower Your Mounjaro Cost in Washington

Start by confirming your insurance formulary status. Call the number on your insurance card and ask whether tirzepatide (brand name Mounjaro) requires prior authorization and what tier it sits on. If covered, register for the Eli Lilly savings card before your first fill.

If your plan denies coverage, your prescriber can file a formulary exception request citing SURPASS trial data and ADA Standards of Care, which recommend GLP-1 or dual GIP/GLP-1 agonists as second-line therapy after metformin for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [3]. The American Diabetes Association's 2024 Standards of Care specifically list tirzepatide among preferred agents for patients needing weight reduction alongside glycemic control [3].

For patients without insurance coverage options, consider these Washington-specific pathways: Lilly's patient assistance program (Lilly Cares) provides free Mounjaro to patients earning below 400% of the federal poverty level. Washington's Apple Health (Medicaid) expansion covers adults up to 138% FPL. Compounded tirzepatide through a licensed Washington 503A pharmacy offers the lowest out-of-pocket monthly cost for cash-pay patients.

Clinical Efficacy Supporting the Investment

Tirzepatide's dual GIP/GLP-1 mechanism produced outcomes that exceeded single-incretin therapies across the SURPASS program. In SURPASS-2, the head-to-head comparison against semaglutide 1 mg demonstrated statistically superior A1c reduction and weight loss at all three tirzepatide doses (5 mg, 10 mg, 15 mg) [10].

The weight management data from SURMOUNT-1 (N=2,539) showed mean weight loss of 22.5% at 72 weeks with tirzepatide 15 mg versus 2.4% with placebo in adults with obesity or overweight with at least one weight-related comorbidity [12]. Dr. Ania Jastreboff, principal investigator of SURMOUNT-1, noted that "the magnitude of weight reduction with tirzepatide is beyond what we have previously seen with approved anti-obesity medications" [12].

For Washington patients evaluating whether the monthly cost is justified, these numbers translate to meaningful clinical endpoints: reduced cardiovascular risk, diabetes remission in a subset of patients, improved sleep apnea scores, and reduced need for concurrent medications (statins, antihypertensives, CPAP). The SURPASS-4 cardiovascular outcomes data showed a 20% reduction in major adverse cardiovascular events with tirzepatide versus insulin glargine, though the study was not powered as a dedicated CVOT [13].

Dose Titration and Total Treatment Cost Over Time

Mounjaro's titration schedule affects total cost planning. Patients start at 2.5 mg weekly for four weeks, increase to 5 mg for four weeks, then may increase in 2.5 mg increments every four weeks to a maximum of 15 mg [1]. Because all doses cost the same ($1,023 per month at retail, $25 with savings card), the titration period does not change monthly spending.

Full titration from 2.5 mg to 15 mg takes a minimum of 20 weeks. Most patients reach their effective maintenance dose between 10 mg and 15 mg by months four through six. A 12-month treatment course at $25 per month (with savings card) totals $300. At retail without discounts, that same year costs $12,276. With compounded tirzepatide at $249 per month, annual cost is $2,988.

The Eli Lilly savings card currently has no stated expiration for eligible patients, though terms may change at annual renewal. Washington patients should plan for the possibility that savings card terms could shift and maintain awareness of alternative cost pathways.